S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
3 Big Box Retail Bets for the Holidays
How Long Does it Take to Become a Profitable Trader?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Biden visits Arizona computer chip site, highlights jobs
Is Autozone Ready To Rally For Another Profitable Lap?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Trump Org. jury seeks clarity as deliberations continue
Biden to visit Arizona computer chip site, highlight jobs
NASDAQ:CRMD

CorMedix - CRMD Stock Forecast, Price & News

$3.96
-0.42 (-9.59%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.96
$4.42
50-Day Range
$2.83
$4.45
52-Week Range
$2.64
$8.02
Volume
431,479 shs
Average Volume
340,971 shs
Market Capitalization
$163.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33

CorMedix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
262.0% Upside
$14.33 Price Target
Short Interest
Bearish
3.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$76,400 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.74) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

889th out of 1,023 stocks

Pharmaceutical Preparations Industry

437th out of 501 stocks

CRMD stock logo

About CorMedix (NASDAQ:CRMD) Stock

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CRMD Stock News Headlines

CorMedix Inc. (CRMD)
CorMedix: Q2 Earnings Snapshot - Greenwich Time
Recap: Cormedix Q2 Earnings - Benzinga
Form 10-Q CorMedix Inc. For: Jun 30 - StreetInsider.com
See More Headlines
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CRMD Company Calendar

Last Earnings
11/08/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRMD
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+262.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,210,000.00
Net Margins
-31,830.43%
Pretax Margin
-32,466.30%

Debt

Sales & Book Value

Annual Sales
$190,000.00
Book Value
$1.65 per share

Miscellaneous

Free Float
39,796,000
Market Cap
$163.48 million
Optionable
Optionable
Beta
2.33

Key Executives

  • Joseph Todisco
    Chief Executive Officer & Director
  • Mathew T. David
    Chief Financial Officer & Executive Vice President
  • Antony E. Pfaffle
    Secretary & Chief Scientific Officer
  • Elizabeth Masson-Hurlburt
    Executive VP-Clinical & Medical Affairs
  • Phoebe Mounts
    EVP, General Counsel, Head-Regulatory & Compliance













CRMD Stock - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings
or view top-rated stocks.

What is CorMedix's stock price forecast for 2023?

3 brokerages have issued 12-month target prices for CorMedix's stock. Their CRMD share price forecasts range from $13.00 to $16.00. On average, they anticipate the company's stock price to reach $14.33 in the next year. This suggests a possible upside of 262.0% from the stock's current price.
View analysts price targets for CRMD
or view top-rated stocks among Wall Street analysts.

How have CRMD shares performed in 2022?

CorMedix's stock was trading at $4.63 at the start of the year. Since then, CRMD stock has decreased by 14.5% and is now trading at $3.96.
View the best growth stocks for 2022 here
.

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our CRMD earnings forecast
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.01 million. CorMedix had a negative net margin of 31,830.43% and a negative trailing twelve-month return on equity of 48.66%.

When did CorMedix's stock split?

CorMedix's stock reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).

What is CorMedix's stock symbol?

CorMedix trades on the NASDAQ under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.35%), BlackRock Inc. (1.53%), State Street Corp (0.41%), Ergoteles LLC (0.39%), Barclays PLC (0.35%) and Two Sigma Investments LP (0.28%). Insiders that own company stock include Alan W Dunton, Elizabeth Masson-Hurlburt, Joseph Todisco, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts and Steven W Lefkowitz.
View institutional ownership trends
.

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $3.96.

How much money does CorMedix make?

CorMedix (NASDAQ:CRMD) has a market capitalization of $163.48 million and generates $190,000.00 in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How can I contact CorMedix?

CorMedix's mailing address is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cormedix.com. The company can be reached via phone at (908) 517-9500, via email at daniel@lifesciadvisors.com, or via fax at 908-429-4307.

This page (NASDAQ:CRMD) was last updated on 12/7/2022 by MarketBeat.com Staff